Preclinical-stage discovery and translational developer of multi-modal, synergistic-targeting therapeutics—immune-stimulatory precision antibody–drug conjugates—designed to enhance efficacy, tolerability and minimize resistance in genetically defined cancers. Platform integrates CRISPR high-throughput functional screening with deep bioinformatics to identify cancer dependencies and prioritize ADC candidates.